Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Difference
    0.0%
    Check dated 2026-04-02T15:34:23.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added to the Record History, replacing the older v3.4.3 entry.
    Difference
    0.0%
    Check dated 2026-03-19T05:59:36.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3. No visible changes to trial information or page behavior.
    Difference
    0.0%
    Check dated 2026-03-12T00:47:11.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the history. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.
    Difference
    0.3%
    Check dated 2026-02-11T12:47:03.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and NIH operating status was added. The page revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T06:51:56.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The history page now includes a glossary option, explains color-coding for additions (green) and deletions (red), and updates the revision banner to Revision: v3.4.0 (replacing v3.3.4).
    Difference
    0.4%
    Check dated 2026-01-28T06:19:41.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.